ARID1A expression in intrahepatic cholangiocarcinoma and its relationship with tumor recurrence,metastasis and tumor-specific immunomarkers
10.3760/cma.j.cn113855-20230212-00058
- VernacularTitle:ARID1A在肝内胆管癌患者中的表达及与肿瘤微环境的关系
- Author:
Chao ZHANG
1
;
Zhuomiaoyu CHEN
;
Qian CHENG
;
Zhao LI
;
Jie GAO
;
Jiye ZHU
Author Information
1. 北京大学人民医院肝胆外科，北京 100044
- Keywords:
Protein interaction domains and motifs;
Cholangiocarcinoma;
Prognosis;
Tumor microenvironment
- From:
Chinese Journal of General Surgery
2023;38(5):362-366
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression level between AT-Rich Interaction Domain 1A(ARID1A) in intrahepatic cholangiocarcinoma (ICC) and the correlation with tumor microenvironment.Methods:The clinicopathological and survival data of 110 ICC patients undergoing radical hepatectomy in Peking University People's Hospital from Jan 2015 to May 2021 were retrospectively analyzed. Immunohistochemical staining was used to detect the expressions of ARID1A , programmed cell death 1 ligand 1( PD-L1) in tumor tissues , programmed cell death protein 1(PD-1) and cluster of differentiation 8(CD8) in the microenvironment. The relationship between ARID1A expression and PD-L1, PD-1, CD8 protein expression was analyzed.Results:Twenty seven patients did not express ARID1A, absence of ARID1A was associated with high PD-L1, PD-1 and CD8 expression ( P<0.05). Multivariate analysis showed ARID1A expression, preoperative CEA level,preoperative CA19-9 level, lymph node metastasis and tumor number were independent risk factors. Conclusion:Absent expression of ARID1A suggests poor prognosis of ICC patients, high expression of PD-L1,PD-1 and CD8 protein in ICC tumor microenvironment with ARID1A-deficient expression suggests a possible prognosis benefit by using anti-PD-1, anti-PD-L1 and other immunotherapy regimens.
